RPG Life Sciences (RPGLIFE) Q4 24/25 earnings summary

Executive summary

• Q4 FY25 revenue grew 12.7%, outpacing the market, with strong profit growth and margin expansion year-over-year.

• Full year FY25 revenue rose 12% to ₹65,343 lakhs, with PAT up 27% to ₹111.6 Cr and margins improving.

• Net profit for the year more than doubled, driven by exceptional profit from land assignment and despite a fire incident.

• Six-year trajectory shows sales up 2.2x, EBITDA up 5x, PBT up 10x, PAT up 11x, and significant margin expansion.

• Recognized for value creation, fair business practices, and multiple industry awards.

Financial highlights

• Q4 EBITDA up 37%, PBT up 41%, PAT up 40% year-over-year; EBITDA margin rose from 17.6% to 21.4%.

• FY25 EBITDA grew 27% to ₹172.3 Cr, margin at 26.4%; PAT margin improved to 17.1%.

• Basic and diluted EPS for FY25 were ₹110.80, up from ₹53.01 in FY24.

• Cash surplus reached INR 266 crore, including operational and exceptional items.

• Exceptional items (land assignment/fire) significantly boosted reported PBT and PAT.

Outlook and guidance

• All business segments (domestic, international, API) expected to drive growth, supported by modernized plants and new product pipeline.

• API business to see growth from 12 new molecules by end FY26/FY27; international formulations to benefit from new launches and market expansion.

• R&D spend expected to remain at 2-3% of sales, possibly rising as more molecules are developed.

• Board recommended a final dividend of ₹20 per share and a special dividend of ₹4 per share, subject to approval.

• Strategic focus on global expansion, new product launches, and M&A opportunities.